117 related articles for article (PubMed ID: 10416014)
1. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):605-7. PubMed ID: 10416014
[TBL] [Abstract][Full Text] [Related]
2. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
[TBL] [Abstract][Full Text] [Related]
3. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
[TBL] [Abstract][Full Text] [Related]
4. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
[TBL] [Abstract][Full Text] [Related]
5. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Comella P; Scoppa G; Daponte A; Musetta G; Anania C; Maiorino A; Curcio C; Casaretti R; Comella G
Cancer; 1994 Oct; 74(7):1874-81. PubMed ID: 8082093
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
[TBL] [Abstract][Full Text] [Related]
7. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
Kosmidis P; Mylonakis N; Fountzilas G; Pavlidis N; Samantas E; Karabelis A; Kattis K; Skarlos D
Ann Oncol; 1996 Jul; 7(5):517-20. PubMed ID: 8839908
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
Chen Y; Perng RP; Yang KY; Lin WC; Wu HW; Tsai CM; Whang-Peng J
Lung Cancer; 2000 Aug; 29(2):139-46. PubMed ID: 10963844
[TBL] [Abstract][Full Text] [Related]
12. Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
De Giorgi U; Rosti G; Ciucci G; Kopf B; Minzi C; Argnani M; Marangolo M
Bone Marrow Transplant; 2007 Oct; 40(8):735-9. PubMed ID: 17700603
[TBL] [Abstract][Full Text] [Related]
13. Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC).
Preti P; Poggi G; Cuomo AM; Robustelli della Cuna FS; Zambelli A; Pavesi L
J Chemother; 1998 Dec; 10(6):492-5. PubMed ID: 9876059
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
Sculier JP; Paesmans M; Thiriaux J; Lecomte J; Bureau G; Giner V; Efremidis A; Lafitte JJ; Berchier MC; Alexopoulos CG; Zacharias C; Mommen P; Ninane V; Klastersky J
J Clin Oncol; 1998 Apr; 16(4):1388-96. PubMed ID: 9552042
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
17. Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
van Zandwijk N; ten Bokkel Huinink WW; Wanders J; Simonetti G; Dubbelman R; Franklin H; van Tinteren H; McVie JG
Semin Oncol; 1990 Feb; 17(1 Suppl 2):16-9. PubMed ID: 2154854
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
[TBL] [Abstract][Full Text] [Related]
19. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
